[ Englisch] What Treatment Options Are Available for Lung Cancer Patients With No Driver Mutations?

Published on

Topics include: Treatments and Understanding

Dr. Alex Spira, Director of the Virginia Cancer Specialists, ASCO President Dr. Bruce Johnson and lung cancer survivor Don Stranathan discuss the latest understanding of lung cancer, state-of the-art testing to plan personalized care, currently approved therapies and research around promising clinical trials to help patients and care partners learn how to be proactive in order to get tomorrow’s medicine today. 

This lung cancer webinar was a SURVIVEiT® program produced in association with US Oncology NetworkVirginia Cancer Specialists and the Precision Medicine for Me initiative and produced by Patient Power. The program was sponsored by SURVIVEiT, a non-profit patient organization, through educational grants they received from Celgene, AbbVie, Foundation Medicine, Novartis and Guardant Health with additional support from Viviphi.

View more programs featuring , , and

Produced in association with , , and

Transcript

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you. 

Don Stranathan:

We’ve been talking a lot about precision medicine and knowing your driver genes. There remains a lot of us who have no known drivers, even after testing. What do the doctors recommend to us, and how do they determine the best course of treatment for us? What kinds of clinical trials are available to patients in these circumstances?

Andrew Schorr:

Dr. Spira, do you want to start with that one?

Dr. Spira:                   

Sure. We all get excited about these driver mutations, the ones we know about, the ones that are still evolving. It’s still a large majority of patients will not be eligible for those, just because they’re—at most, they make up about 40 percent of patients, looking at all of them.

What you want to be asking is, am I a candidate for immunotherapy? You want to be asking about what’s called your PDL status. We all hope, by the way, there’s gonna be a better test for that than we are using currently in the next few years. If you’re interested in a clinical study, you want to ask, is there one for me? Is it convenient? Do I want to do it? How much more time is it going to involve? What are the risks? I personally think everyone should be asking for a clinical study. At the best we have, our treatments are still not good enough. So, if there’s something that makes sense, yeah, you want to be asking about participating in it. Many of our patients still get chemo. Chemo’s gotten a little bit of short shrift. But in all oncology practices, most of our patients still will be getting chemotherapy now and for the foreseeable future as well, and there’s nothing wrong with it. Chemo by itself has actually gotten a lot easier as well. So don’t be discouraged, disappointed, angry or anything. Just make the best of it that you can. And again, if there’s a clinical trial, ask about it.

Dr. Johnson:

I’d like to emphasize that just because you don’t have one at the time you’re diagnosed doesn’t mean it won’t become available when we use other treatments. The second thing is that—and one of the things I try to do is that, as Dr. Spira mentioned, you want to have the PDL1 testing, because some of the people can get treated with immunotherapy. The other thing I try to do with almost all my patients who don’t have an identifiable driver is to put them on combination immunotherapy agents.

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you. 

Advertisement
tritt unserer Gemeinschaft bei Registrieren Sie sich für Veranstaltungen Lesen Sie unseren neuesten Blog
Advertisement

Page last updated on August 14, 2017